Intrinsiqs

Is Tekla Life Sciences Investors overvalued?

Tekla Life Sciences Investors (HQL) — key valuation metrics and fundamentals.

No verdict
Price
$20.11
Fair value
Current P/E
Normal P/E
Market cap
$609.8M
Dividend yield
Return on equity
Sector
Financial Services

See the full interactive analysis →

Fair value compares HQL's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 30 Jun 2026.